Tenax Therapeutics, Inc.

TENX

$1.83

+2.53%

2026-09-04 09:46:36 EDT+$0.05

Healthcare

Biotechnology

NASDAQ

Active Trading

Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions ...

Price Action of TENX

$1.83

+2.53%+$0.05

High—

Low—

52W High-90.6%

Rel. vol—

Interval

Range16m

Volume—SMA5SMA10

—

Tenax Therapeutics, Inc. is a specialized pharmaceutical company dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Founded in 1967 and headquartered in Chapel Hill, North Carolina, the company was originally known as Oxygen Biotherapeutics, Inc. before rebranding to ...Tenax Therapeutics, Inc. is a specialized pharmaceutical company dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Founded in 1967 and headquartered in Chapel Hill, North Carolina, the company was originally known as Oxygen Biotherapeutics, Inc. before rebranding to Tenax Therapeutics in September 2014. The company's product pipeline is centered on treatments for pulmonary hypertension, especially that linked to heart failure with preserved ejection fraction (HFpEF). Its lead product candidates include TNX-103 and TNX-102 (both levosimendan), which have completed Phase II clinical trials, and TNX-201 (imatinib), a tyrosine kinase inhibitor designed for pulmonary arterial hypertension. The company is currently in Phase 3 development stages, leveraging clinical insights to guide its innovative drug development strategy. Financially, Tenax Therapeutics is a small-cap company with a market capitalization of approximately $36 million, no revenue, and a negative net income, reflecting its development-stage status. The company has a strong current ratio of 15.07, indicating ample liquidity, and a low price-to-book ratio of 0.611. With only 14 full-time employees, the company operates with a lean team led by CEO Christopher T. Giordano, who brings over 20 years of clinical development experience. The management team has decades of experience developing and commercializing cardiovascular products. Despite financial challenges typical of early-stage biotech firms, Tenax Therapeutics remains committed to addressing unmet medical needs in cardiopulmonary diseases, with a focus on advancing its pipeline through clinical trials and potential regulatory approvals.ExpandCollapse

Founded

1967

Employees

CEO

Christopher T. Giordano

Full Name

Tenax Therapeutics, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-61.55%

Market Cap

$0.07B

Current Ratio

15.07

WACC

8.92%

ROIC

-57.97%

Contact Information

https://www.tenaxthera.com

919 855 2100

101 Glen Lennox Drive, Chapel Hill, NC 27517

Key Metrics of TENX

Snapshot

Latest / TTM · 6 periods

Market Cap

$68.30M

ROCE

-60.4%

EV / EBITDA

1.07x

-2.3% YoY

FCF Yield

-97.5%

-90.0% YoY

Cash Conversion Cycle

0.0d

Current Ratio

15.07

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of TENX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-1.22x

n/a

Debt / Equity

0.00

n/a

Current Ratio

15.07

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of TENX

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.36 · Revenue $0.00 · 5 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.38 · Revenue $0.00 · 5 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-1.45 · Revenue $4.16M · 8 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.39 · Revenue $0.00 · 3 analysts

Recent history

Jul 31, 2026
Q2 FY2026 · Results reported
EPS $-0.35 · Revenue $0.00
View filing
May 12, 2026
Q1 FY2026 · Results reported
EPS $-0.35 · Revenue $0.00
View filing
Mar 10, 2026
FY2025 · Annual results
EPS $-1.34 · Revenue $0.00
View filing
Nov 12, 2025
Q3 FY2025 · Results reported
EPS $-0.40 · Revenue $0.00
View filing
Aug 13, 2025
Q2 FY2025 · Results reported
EPS $-0.27 · Revenue $0.00
View filing
May 14, 2025
Q1 FY2025 · Results reported
EPS $-0.28 · Revenue $0.00
View filing

Financial Statements of TENX

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-52.6M	-198.8%	-13.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-35.8M	-141.7%	-52.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	0.0%	—	—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	14.56x	-29.3%	+3.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$104.2M	+7.8%	-1.2%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.34 vs -1.37	+2.4%	-0.35 vs -0.36	+2.8%
Revenue Surprise	$0 vs $2.0M	-100.0%	—	—

Insider Transactions of TENX

Acquisitions (A)

Since Jul 13, 2026

Disposals (D)

Since Jul 13, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Sep 2, 2026	ADAR1 Capital Management, LLC	10 percent owner	Common Stock	A	187,704	$1.80
Sep 1, 2026	ADAR1 Capital Management, LLC	10 percent owner	Common Stock	A	179,058	$1.80
Aug 31, 2026	ADAR1 Capital Management, LLC	10 percent owner	Common Stock	A	403,571	$1.79
Aug 24, 2026	ADAR1 Capital Management, LLC	10 percent owner	Common Stock	A	107,374	$1.75
Aug 21, 2026	ADAR1 Capital Management, LLC	10 percent owner	Common Stock	A	716,369	$1.77

Leadership Team of TENX

8 executives

Name	Title	Compensation	Gender	Year Born	Status
Christopher T. Giordano	Chief Executive Officer, President & Director	USD 813,633	Male	1975	Active
Stuart Rich	Chief Medical Officer & Director	USD 490,217	—	1950	Active
Thomas A. McGauley	Principal Financial Officer & Principal Accounting Officer	USD 475,498	Male	1973	Active
Thomas R. Staab	Chief Financial Officer	—	Male	1968	Active
So-Young Kim	Executive Vice President of Clinical Development & Strategy	—	—	—	Active
Doug Randall	Chief Business Officer	—	Male	—	Active
Douglas Hay	Executive Vice President of Regulatory Affairs	—	—	—	Active
Timothy G. Healey	Chief Commercial Officer	—	Male	1966	Active

Recent News of TENX

GuruFocus8/19/2026Neutral

Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky

Tenax Therapeutics (TENX) Securities Investigation Notice - Levi and Korsinsky PR Newswire NEW YORK, Aug. 19, 2026

PRNewsWire8/19/2026Neutral

Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky

Tenax Therapeutics shares fell approximately 84% to 85% after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations on behalf of TENX investors who suffered losses.

GlobeNewsWire8/17/2026Neutral

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX)

Tenax Therapeutics shares lost roughly 84% to 85% of their value after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations. Tenax Therapeutics shares lost roughly 84% to 85% of their value after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations.

GuruFocus8/16/2026Neutral

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv

Business Wire8/16/2026Neutral

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $TENX--TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law.

Historical Employee Count of TENX

Current

Change

+250.00%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	14	10-K	Mar 10, 2026	View
Dec 31, 2024	4	10-K	Mar 25, 2025	View
Dec 31, 2023	5	10-K	Mar 28, 2024	View
Dec 31, 2022	7	10-K	Mar 31, 2023	View
Dec 31, 2021	8	10-K	Mar 29, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Tenax Therapeutics, Inc.